ClinicalTrials.gg
CompletedNCT06459609CRAVPROTUpdated Mar 23, 2026

Effect of Protein Supplementation on Craving in Subjects Hospitalised for Addiction Treatment

An interventional study of protein supplementation in Addiction, sponsored by Centre Hospitalier de PAU. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Centre Hospitalier de PAU · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 77 studies in Behavior, Addictive with a site in France — 33 open to participants now, 34 under way, none of them phase 3. Behavior, Addictive · France.

Enrollment
31st of 34
28 · median 88
Started
2024
with 5 others
No phase
33 of 77
13 open now
Registered
56th of 77
by date

Among the 77 studies in Behavior, Addictive with a site in France, this one is the 31st largest by enrollment of the 34 interventional ones that give a count, is one of 6 that started in 2024, is one of 33 with no phase, and was the 56th registered.

Behavior, Addictive

522 studies on the registry are indexed under Behavior, Addictive; 125 are open to participants now.

Browse Behavior, Addictive studies →

Open to participants now

33 of the 77 studies in Behavior, Addictive with a site in France are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 81 Behavior, Addictive studies recruiting now, 45 (56%) set no upper age limit and 34 (42%) stop at 75 or younger; 7 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Behavior, Addictive with a site in France, or all of them as a file.
02

Study summary

Moncentric pilot study conducted in the addictology department of the Pau Hospital, designed to demonstrate the benefit of protein supplementation on craving in patients with a substance use disorder at the start of their treatment for addiction.

This study will be conducted according a crossover design with a one-week phase with protein supplementation (P) and a one-week phase without protein supplementation (SP).

Read the detailed description

Addiction is a chronic psychiatric disorder characterised by the loss of control over the use of rewarding substances or behaviours, despite the accumulated damage. Craving, defined as an irrepressible, obsessive craving, is a key early symptom of addiction. Protein supplementation could reduce this craving. Nutritional abnormalities aggravate addictions but no study have directly assessed the impact of protein supplementation on craving. Evidence suggests that protein supplementation reduces cravings for sugary and hyperpalatable foods, which could extend to rewarding substances. The hypothesis is that this supplementation reduces the intensity, duration and frequency of craving in withdrawal patients by influencing dopaminergic reward circuits.

Protein supplementation takes the form of a powder sachet mixed with yoghurt or compote. It will be given twice a day, at the same time (8am and 4pm).

Patients will be enrolled at the admission to the addiction unit. They will be assessed psychologically, addictologically and nutritionally for one week and then will be randomised. Patients will be asked to assess their cravings, dietary needs, consumption of addictive substances and palatable foods.

03

Conditions studied

  • Addiction

Browse trials for

Keywords

  • addiction
  • craving
  • protein supplementation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female
  • Aged 18 and over
  • Admitted for complex care in the addictology department
  • Person affiliated to or benefiting from a social security scheme
  • Free, informed and written consent signed by the participant and the investigator

Exclusion criteria

Exclusion Criteria:

  • Allergy to milk protein
  • Admitted to hospital for less than 3 weeks
  • Severe somatic or psychiatric pathology incompatible with understanding assessment tools
  • Difficulty understanding and/or writing French
  • Presumed non-compliant in completing the patient diary
  • Person participating in another research study with an exclusion period still in progress
  • Person under legal protection (guardianship, curatorship)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Other
    P - SP

    1 week with protein supplementation (P) then one week without protein supplementation (SP)

    Dietary Supplement: protein supplementation

  • Other
    SP - P

    1 week without protein supplementation (SP) then one week with protein supplementation (P)

    Dietary Supplement: protein supplementation

Interventions

  • Dietary supplementprotein supplementation

    Protein supplementation takes the form of a powder sachet mixed with yoghurt or compote. It will be given twice a day, at the same time.

06

What researchers measure

Primary outcomes

  1. Evolution of craving for the main substance

    Evaluation of the evolution of craving for the main substance in patients with a substance use disorder in association with protein supplementation. It will be a self-assessment by the patient, using a visual analogue craving scale ranging from 1 'no craving' to 7 'extreme craving'.

    Time frame: This outcome will be assessed twice a day (morning and afternoon) from day 8 to day 21, during the period with and without protein supplementation.

Secondary outcomes

  1. Food craving evolution

    Food craving will be assessed by patient self-assessment using a visual analogue craving scale ranging from 1 'no craving' to 7 'extreme craving'.

    Time frame: This outcome will be assessed twice a day (morning and evening) from Day 8 to Day 21 during the period with and without protein supplementation.

  2. Consumption of hyperpalatable foods

    Consumption of hyperpalatable foods will be assessed by patient self-evaluation, twice a day from D8 to D21 during the period with and without protein supplementation, using a visual scale assessing the extent to which the patient consumed hyperpalatable foods outside of meals, this scale ranging from 1 'not at all' to 7 'very much'.

    Time frame: This outcome will be assessed every day from Day 8 to Day 21 during the period with and without protein supplementation.

  3. Influence of the severity of addiction

    Influence of the severity of addiction measured using the Addiction Severity Index (ASI) questionnaire

    Time frame: Evaluation at the inclusion

  4. Influence of psychiatric comorbidities

    Influence of psychiatric comorbidities (mood disorders and anxiety disorders) assessed using the MINI (Mini International Neuropsychiatric Interview)

    Time frame: Evaluation at the inclusion

07

Study locations

1 site
  • CH de Pau
    Pau, 64000, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Sep 2025, 11 months.

Of 148 non-industry interventional studies with no phase under Behavior, Addictive, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 42. This study's 11 months is below that.

Counting every sponsor, half of 156 studies reached it within 26 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2024
First posted
Jun 14, 2024
StartActual
Oct 1, 2024
Primary completionActual
Sep 24, 2025
CompletionActual
Sep 24, 2025
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06459609
Lead sponsor
Centre Hospitalier de PAU
Responsible party
Sponsor
First posted
Jun 14, 2024
Start date
Oct 1, 2024
Primary completion
Sep 24, 2025
Completion
Sep 24, 2025
Last update
Mar 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion